

1 **Title: Synergy between the phage endolysin LysH5 and nisin to kill *Staphylococcus***
2 ***aureus* in pasteurized milk**

3

4 **Authors:** Pilar García*, Beatriz Martínez, Lorena Rodríguez and Ana Rodríguez

5

6 **Addresses:** Instituto de Productos Lácteos de Asturias (IPLA-CSIC). Apdo. 85. 33300-

7 Villaviciosa, Asturias, Spain.

8

9 ***Corresponding author:** Dr. Pilar García

10 IPLA-CSIC, Apdo. 85. 33300-Villaviciosa, Asturias, Spain.

11 **e-mail:** pgarcia@ipla.csic.es

12 **Phone:** +34 985 89 21 31

13 **Fax:** +34 985 89 22 33

14

15

16

17

18

19

20

21

22

23

24

25

26 **Abstract**

27

28 Phage-encoded endolysins are recently considered as new biocontrol tools to inhibit
29 pathogens in food. In this work, we have studied the ionic requirements for optimal lytic
30 activity of LysH5, the endolysin encoded by the staphylococcal bacteriophage phi-
31 SauS-IPLA88. LysH5 activity was inhibited by the presence of Mn^{++} and Zn^{++} and
32 enhanced by Ca^{++} , Mg^{++} and NaCl. When LysH5 was combined with nisin, a
33 bacteriocin currently used as a biopreservative in food, a strong synergistic effect was
34 observed. The Minimum Inhibitory Concentrations of nisin and LysH5 were reduced
35 64- and 16-fold, respectively, as determined in checkerboard microtitre tests. In
36 addition, nisin enhanced 8-fold the lytic activity of LysH5 on cell suspensions. The
37 synergy observed *in vitro* was confirmed in challenge assays in pasteurized milk
38 contaminated with *S. aureus* Sa9. Clearance of the pathogen was only achieved by the
39 combined activity of both antimicrobials. As far as we know, this is the first study that
40 exploits the possibilities of hurdle technology combining a phage-encoded endolysin
41 and the bacteriocin nisin for efficient *S. aureus* inhibition in milk.

42

43 **Keywords:** endolysin, natural antimicrobials, dairy products, biopreservation.

44

45

46

47

48

49 **1. Introduction**

50

51 *Staphylococcus aureus* is a major human pathogen that causes a wide range of
52 diseases including food poisoning due to the production of enterotoxins (Le Loir et al.,
53 2003). Milk and dairy products are often implicated in staphylococcal outbreaks (De
54 Buyser et al., 2001; Delbes et al., 2006). During the elaboration of dairy products,
55 contamination by *S. aureus* may come from several sources including raw milk (notably
56 milk from mastitic cows), biofilms in the processing plant environment as well as
57 healthy human carriers.

58 Nisin, a bacteriocin produced by some strains of *Lactococcus lactis*, is used in
59 more than 40 countries as a natural preservative in foods including dairy products
60 (Gálvez et al., 2007). The combination of this bacteriocin with heat and non-thermal
61 treatments, such as high pressure, pulsed electric fields and other antimicrobials has
62 been also approached (Sobrino-López and Martín-Belloso, 2008). However, many
63 reports have suggested that the ultimate failure of bacteriocin-based preservation
64 systems may be due to the eventual growth of nisin-resistant strains that could
65 compromise its use to control food-borne pathogens such as *Listeria monocytogenes*
66 (Gravesen et al., 2002), *Clostridium botulinum* (Mazzotta et al., 1997), and *S. aureus*
67 (Peschel et al., 1999).

68 Bacteriophage lytic enzymes have also attracted considerable interest as novel
69 antimicrobials, mostly against gram-positive bacteria, and have been used for
70 controlling bacterial infections and preventing pathogen colonization of mucosal
71 membranes (Fischetti, 2008). Mixtures of endolysins with other antimicrobial agents
72 have been previously assayed. Synergy between lysostaphin and the lysK endolysin
73 against *S. aureus* has been reported (Becker et al., 2008). Similarly, the phage lytic

74 enzyme Cpl-1 acted synergistically with gentamycin, penicillin and with the phage
75 endolysin Pal against several penicillin-resistant and sensitive *Streptococcus*
76 *pneumoniae* strains (Loeffler and Fischetti, 2003; Djurkovic et al., 2005). On the
77 contrary, there are hardly any reports on the combined activity of phage endolysins with
78 food preservatives or other preservation technologies. Very recently, it has been shown
79 that the endolysins KZ144 and EL188 sensitize *Pseudomonas aeruginosa* to high
80 hydrostatic pressure (Briers et al., 2008)

81 We have previously identified and characterized the endolysin LysH5 encoded
82 by the *S. aureus* phage phi-SauS-IPLA88. Bioinformatic analysis of the LysH5 protein
83 sequence revealed three putative domains, a cysteine, histidine-dependent
84 amidohydrolase/peptidase (CHAP) domain, an amidase-2 domain, and a C-terminal
85 SH3b cell wall-binding domain. LysH5 lysed a wide range of staphylococci including
86 bovine and human *S. aureus* and *Staphylococcus epidermidis* and it also inhibited *S.*
87 *aureus* growth in milk (Obeso et al., 2008). In this work, we have analysed the ionic
88 requirements for LysH5 activity and evaluated possible synergistic effects with the
89 bacteriocin nisin in order to explore new biopreservation strategies based on hurdle
90 technology to effectively inhibit *S. aureus* in milk.

91

92 **2. Materials and Methods**

93

94 **2.1. Bacterial strains and growth conditions.** *S. aureus* Sa9 was used as the indicator
95 strain for endolysin activity. The organism was grown in 2xYT broth (Sambrook et al.,
96 1989) at 37 °C for 18 h with vigorous shaking. *E. coli* BL21(DE3)/pLys containing the
97 pRSETB-lysH5 plasmid was used to overexpressed the endolysin LysH5 (Obeso et
98 al., 2008).

100 **2.2. LysH5 purification.** Exponentially cultures (OD₆₀₀ nm of 0.6-0.8) growing in
101 shaking flasks at 37 °C were induced with 1 mM IPTG (isopropyl-beta-D-
102 thiogalactopyranoside). Three hours after induction, cells were pelleted, washed with 20
103 mM NaH₂PO₄, pH 7.4 and frozen at -20 °C. For protein purification, 500 ml culture cell
104 pellets were resuspended in 40 ml of cell resuspension buffer (iFOLD Protein Refolding
105 System 2, Novagen, Madison, USA) and sonicated (15×5 s pulses with 15 s recovery on
106 ice) following the manufacturer's instructions. Inclusion bodies containing LysH5 were
107 obtained and stored at -80 °C. They were further desnaturalized in iFold Guanidine
108 desnaturalization buffer and folding of the protein was monitored in the iFold protein
109 refolding matrix that includes 96 buffer conditions. The refolded protein was added to
110 0.5 ml Ni-NTA (nickel matrix) slurry and eluted according to the manufacturer's
111 instructions (Qiagen, Valencia, CA). Fractions containing LysH5 were dialyzed against
112 20 mM NaH₂PO₄ buffer, pH 7.0, diluted in glycerol (50% final concentration), and
113 stored at -80 °C. Purity of each preparation was determined in 15% (w/v) SDS-PAGE
114 gels. Electrophoresis was conducted in Tris-Glycine buffer at 20 mA for 1 h in the
115 BioRad Mini-Protean gel apparatus. Protein was quantified by the Quick Start Bradford
116 Protein Assay (BioRad, Hercules, CA).

117

118 **2.3. Turbidity reduction assays.** The turbidity assay was performed in a Microplate
119 Spectrophotometer Benchmark Plus (BioRad, Hercules, CA) as previously described
120 (Obeso et al., 2008). The enzymatic activity of LysH5 was determined in salt buffers
121 composed of 50 mM phosphate buffer, pH 7.0 with NaCl ranging from 0 to 500 mM.
122 Activity was also assayed in the presence of several cations (CaCl₂, MgCl₂, MnCl₂ and
123 ZnCl₂) at concentrations ranging from 0 to 1 mM.

124

125 **2.4. Checkerboard microtiter tests.** Susceptibilities to nisin and the endolysin, and the
126 putative synergism between both antimicrobials, were determined by microdilution in
127 microtiter plates as previously described (Martínez et al., 2008). Minimum inhibitory
128 concentrations (MICs) of nisin and endolysin were defined as the lowest concentration
129 at which growth of the indicator organism was totally inhibited after 18 h incubation at
130 37 °C. To calculate MICs, two-fold serial dilutions of nisin from 3 µg/ml to 0.002 µg/ml
131 and endolysin from 50 U/ml to 0.78 U/ml were used. To determine the synergistic effect
132 between nisin and endolysin a checkerboard test (White et al., 1996) was carried out.
133 Wells containing nisin (0.75 µg/ml to 0.00075 µg/ml) were combined with LysH5 (50
134 U/ml to 0.78 U/ml). In this test, up to 45 different combinations of nisin and the
135 endolysin were tested. Controls with each nisin or endolysin concentration were also
136 included separately. The fractional inhibitory concentration (FIC) was calculated as the
137 MIC of the antimicrobial in combination divided by the MIC of the antimicrobial acting
138 alone. Strong synergy exists if the sum of the two FICs [$\sum FIC = FIC_A + FIC_B$] is <0.5
139 (Hall et al., 1983). All the experiments were performed in duplicate.

140 A similar checkerboard test was performed with *S. aureus* Sa9 suspensions in 50 mM
141 phosphate buffer, pH 7.0, to a final OD_{600 nm} of 1.5 as described in section 2.3.
142 Minimum lysis concentrations (MLCs) of nisin and endolysin individually and in
143 combination were determined. MLCs were defined as the lowest concentration at which
144 total cell lysis was obtained after 15 min of incubation at 37 °C. The fractional
145 inhibitory concentration (FIC) was calculated as described above. In this case, wells
146 containing nisin (6 µg/ml to 0.005 µg/ml) were combined with endolysin (5 U/ml to
147 0.078 U/ml).

148

149 **2.5. Challenge tests in pasteurized milk.** Commercial pasteurized milk was inoculated
150 with 10^2 cfu/ml and 10^5 cfu/ml of *S. aureus* Sa9. Immediately after, nisin (0.37 µg/ml
151 and 0.75 µg/ml), endolysin (7.5 U/ml and 15 U/ml) and a mixture of both, were also
152 added. The milk was incubated at 37 °C without shaking and samples were taken at
153 various times. Survival of *S. aureus* was determined by plating decimal dilutions on
154 plates of Baird–Parker selective agar (Scharlab, Barcelona, Spain) which were
155 incubated at 37 °C for 24 h.

156

157 **3. Results and Discussion.**

158

159 **3.1. Improved purification and lytic activity of the endolysin LysH5.** Previous
160 attempts to purify the endolysin LysH5 after overexpression of *E. coli* BL21(DE3)/pLys
161 cultures containing pRSETB-lysH5 (Obeso et al., 2008) gave low yields owing to the
162 poor solubility of the protein. Therefore, we proceeded to improve the recovery of
163 LysH5 from inclusion bodies and subsequent refolding. Using the iFOLD Protein
164 Refolding System 2, the highest solubility was obtained by refolding in buffer A: CHES
165 50 mM, PEG 3350 0.06%, CaCl₂ 0.25 mM, MnCl₂ 0.25 mM, ZnCl₂ 0.25 mM, TCEP 1
166 mM, pH 9. In this way, the purification yield was 128 Units per ml of induced *E. coli*
167 culture, which means an increase of 35 times compared to our previous reports (Obeso
168 et al., 2008).

169 To assess the optimal conditions for LysH5 activity, turbidity reduction assays
170 with *S. aureus* Sa9 cells were carried out using 4 µg of LysH5 (10 U/ml, final
171 concentration). Several concentrations of NaCl and the presence of other cations (CaCl₂,
172 MgCl₂, MnCl₂ and ZnCl₂) were tested (Fig. 1). LysH5 activity was clearly inhibited by
173 the presence of ZnCl₂ and MnCl₂, even at low concentrations (Fig. 1A). On the contrary,

174 MgCl₂ and CaCl₂ clearly enhanced activity of LysH5. A similar requirement of Ca²⁺ (2-
175 3 mM) was described for the *S. aureus* bacteriophage phi11 endolysin (Donovan et al.,
176 2006). It has also been suggested that divalent cations may be associated with the pure
177 enzymes and be required for activity and/or structural stability of peptidoglycan
178 hydrolases (Llull et al., 2006). These Ca²⁺ values are in accordance with the calcium
179 content in milk and, thereby, may promote the lytic activity of these proteins in this
180 food matrix. The endolysin LysH5 showed higher activity in the presence of any NaCl
181 concentration tested with maximal activity at concentrations close to 100 mM (Fig. 1B).
182 According to these results, the optimal buffer conditions for the turbidity reduction
183 assays were defined as: phosphate buffer 50 mM, CaCl₂ 1 mM, MgCl₂ 1 mM, NaCl 100
184 mM, pH 7.0.

185

186 **3.2. *In vitro* synergy between nisin and LysH5.** Initially, minimum inhibitory
187 concentrations (MICs) of nisin and the endolysin were determined by using
188 exponentially growing cultures of *S. aureus* Sa9. The MICs of nisin and LysH5 were 3
189 µg/ml and 50 U/ml, respectively (data not shown). When both nisin and the endolysin
190 were combined in the checkerboard microtiter test, a synergistic effect was observed. In
191 the presence of subinhibitory concentrations of nisin, a lower endolysin concentration
192 was needed to fully inhibit *S. aureus* Sa9 growth (Fig. 2A). Thus, growth inhibition by
193 the two antimicrobials in combination was greater than either alone. From the
194 checkerboard test, it could be concluded that the most effective conditions to inhibit
195 bacterial growth were 0.75 µg/ml and 3.1 U/ml, or 0.045 µg/ml and 12.5 U/ml for nisin
196 and LysH5, respectively. These values implied up to a 64-fold and 16-fold reduction of
197 the nisin and endolysin MICs, respectively, when used in combination. The average

198 Σ FIC was 0.155 ± 0.06 ($n=3$) highlighting the strong synergy between both
199 antimicrobials.

200 Many approaches to enhancing the antagonistic activity of nisin and expand its
201 range of application have been tried. Nisin has been found to act synergistically with
202 various antimicrobials including chelators (Fang and Tsai, 2003), small molecular
203 weight substances from plants (Ettayebi et al., 2000), reuterin (Arqués et al., 2004),
204 proteins such as lysozyme and lactoferrin (Branen and Davidson, 2004) and milk-
205 derived peptides (López-Expósito et al., 2008). The positive interaction between the
206 endolysin LysH5 and nisin could be due to a better access to their respective cleavage
207 and binding site promoted by the other compound, or based on an enhanced
208 peptidoglycan hydrolase activity through the dissipation of the membrane proton motive
209 force by nisin. It has been shown that nisin triggered activity of the endolysin Lys44 by
210 mimicking the holin disruption of the cytoplasmic membrane electrical and chemical
211 gradients (Nascimiento et al., 2008).

212 To get a deeper insight into the synergy between nisin and LysH5, a
213 checkerboard test was performed using metabolic arrested cells in buffer. These are the
214 conditions which are routinely assayed to measure peptidoglycan hydrolytic activities.
215 Under these conditions, the minimum lysis concentration (MLC) of LysH5 was 2.5
216 U/ml while nisin (more than 6 μ g/ml) did not lyse the cells (data not shown). In this
217 assay, the effective LysH5 concentration was lower than that needed to inhibit *S. aureus*
218 growth in the MIC assay, showing that cell suspensions are more sensitive to the
219 endolysin action than exponentially growing cells. It is possible to speculate that the
220 higher sensitivity of *S. aureus* cell suspensions might be due to a lower peptidoglycan
221 turnover in these metabolic arrested cells which would be unable to counteract the
222 peptidoglycan breaks generated by LysH5. Nevertheless, the endolysin MLC against *S.*

223 *aureus* suspensions could be even reduced in the presence of nisin (Fig. 2B). The most
224 effective conditions to properly lyse *S. aureus* Sa9 bacterial suspensions identified in
225 this assay were 1.5 µg/ml and 0.3 U/ml or 0.180 µg/ml and 1.25 U/ml of nisin and
226 endolysin, respectively. The Σ FIC for *S. aureus* suspensions was 0.077 ± 0.01 indicating
227 again a strong synergistic activity where, the presence of nisin enhanced LysH5 activity
228 up to 8-fold. These results further support that LysH5 activity might be increased by the
229 permeabilization of the cytoplasmic membrane by nisin as described for the endolysin
230 Lys44 (Nascimento et al., 2008). Also, partial activation of autolysins by nisin may
231 occur and facilitate LysH5 activity (Bierbaum and Sahl, 1985). Nonetheless, the basis of
232 the synergy between nisin and LysH5 deserves further investigation.

233

234 **3.3. Enhanced inhibition of *S. aureus* growth in milk.** In view of the synergy between
235 nisin and LysH5 *in vitro*, we proceeded to verify if a combination of both antimicrobials
236 would be more effective to inhibit *S. aureus* growth in milk. Challenge assays in
237 pasteurized milk were carried out using two levels of *S. aureus* Sa9 contamination (10^2
238 cfu/ml and 10^5 cfu/ml). Nisin (0.37 µg/ml and 0.75 µg/ml), endolysin LysH5 (7.5 U/ml
239 and 15 U/ml) and a mixture of both were tested. The addition of LysH5 had only a
240 slight inhibitory effect on *S. aureus* growth regardless the contamination level (Fig. 3).
241 On the contrary, the addition of nisin inhibited *S. aureus* multiplication in milk and kept
242 the initial cell counts constant (Fig. 3). However, a complete clearance of the pathogen
243 was only obtained in the presence of the mixture (LysH5 and nisin) after 6 h of
244 incubation. The inhibitory effect of both antimicrobials was already noticeable after 4 h
245 and the counts were 4 and 6 unit-log below the control culture at both low (Fig. 3A) and
246 higher (Fig. 3B) contamination levels, respectively.

247 As anticipated by the *in vitro* results, the mixture was also more efficient in a food
248 matrix than each antimicrobial alone. A similar synergistic effect between nisin and
249 bacteriophages against *S. aureus* in milk was previously described in short-time
250 challenge tests (Martínez et al., 2008). However, bacteriophage cross-resistance arose in
251 nisin-adapted mutants. This seems not to be the case with the endolysin LysH5 as these
252 nisin mutants were still sensitive to LysH5 (data not shown). Another advantage over
253 bacteriophages is that the combination of LysH5 and nisin was also successful at low
254 pathogen concentration, opposite to the bacteriophages that require a minimum host
255 threshold to be effective (Cairns et al., 2009). In conclusion, our results support the use
256 of phage endolysins as non-traditional food preservatives in combination with the
257 commonly used preservative nisin to inhibit pathogens in food matrices more
258 efficiently. Further studies to determine endolysin stability under food processing
259 conditions, as well as oral toxicity studies are in progress.

260

261 **4. Acknowledgments**

262 This research study was supported by grant AGL2009-13144-C02-01 from the Ministry
263 of Science and Innovation of Spain and IB08-052 from FICYT (Regional Government
264 of Asturias).L. R. is a fellow of the Research Regional Program FICYT.

265

266 **5. References**

267

268 Arqués, J.L., Fernández, J., Gaya, P., Nuñez, M., Rodríguez, E., Medina, M., 2004.
269 Antimicrobial activity of reuterin in combination with nisin against food-borne
270 pathogens. *International Journal of Food Microbiology* 95, 225-229.

271

272 Becker, S.C., Foster-Frey, J., Donovan, D.M., 2008. The phage K lytic enzyme LysK
273 and lysostaphin act synergistically to kill MRSA. FEMS Microbiology Letters 287, 185-
274 191.

275

276 Bierbaum, G., Sahl, H.G., 1985. Induction of autolysis of staphylococci by the basic
277 peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic
278 enzymes. Archives of Microbiology 141, 249-254.

279

280 Branen, J.K., Davidson, P.M., 2004. Enhancement of nisin, lysozyme, and monolaurin
281 antimicrobial activities by ethylenediaminetetraacetic acid and lactoferrin. International
282 Journal of Food Microbiology 90, 63-74.

283

284 Briers, Y., Cornelissen, A., Aertsen, A., Hertveldt, K., Michiels, C.W., Volckaert, G.,
285 Lavigne, R., 2008. Analysis of outer membrane permeability of *Pseudomonas*
286 *aeruginosa* and bactericidal activity of endolysins KZ144 and EL188 under high
287 hydrostatic pressure. FEMS Microbiology Letters 280, 113-119.

288

289 Cairns, B.J., Timms, A.R., Jansen, V.A., Connerton, I.F, Payne, R.J., 2009. Quantitative
290 models of *in vitro* bacteriophage-host dynamics and their application to phage therapy.
291 PLoS Pathoges 5(1):e1000253.

292

293 De Buyser, M.L., Dufour, B., Maire, M., Lafarge, V., 2001. Implication of milk and
294 milk products in food-borne diseases in France and in different industrialised countries.
295 International Journal of Food Microbiology 67, 1-17.

296

297 Delbes, C., Alomar, J., Chougui, N., Martin, J.F, Montel, M.C., 2006. *Staphylococcus*
298 *aureus* growth and enterotoxin production during the manufacture of uncooked,
299 semihard cheese from cows' raw milk. Journal of Food Protection 69, 2161-2167.
300

301 Djurkovic, S., Loeffler, J.M., Fischetti V.A., 2005. Synergistic killing of *Streptococcus*
302 *pneumoniae* with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin
303 depends on the level of penicillin resistance. Antimicrobial Agents and Chemotherapy
304 49, 1225-1228.
305

306 Donovan, D.M., Lardeo, M., Foster-Frey, J., 2006. Lysis of staphylococcal mastitis
307 pathogens by bacteriophage phi11 endolysin. FEMS Microbiology Letters 265(1), 133-
308 139.
309

310 Ettayebi, K., El Yamani, J., Rossi-Hassani B., 2000. Synergistic effects of nisin and
311 thymol on antimicrobial activities in *Listeria monocytogenes* and *Bacillus subtilis*.
312 FEMS Microbiology Letters 183, 191-195.
313

314 Fang, T.J., Tsai, H., 2003. Growth patterns of *Escherichia coli* O157:H7 in ground beef
315 treated with nisin, chelators, organic acids and their combinations immobilized in
316 calcium alginate gels. Food Microbiology 20, 243-253.
317

318 Fischetti, V.A., 2008. Bacteriophage lysins as effective antibacterials. Current Opinion
319 in Microbiology 11, 393-400.
320

321 Gálvez, A., Abriouel, H., López, R.L., Omar, N.B., 2007. Bacteriocin-based strategies
322 for food biopreservation. *International Journal of Food Microbiology* 120, 51-70.
323

324 Gravesen, A., Jydegaard Axelsen, A.M., Mendes da Silva, J., Hansen, T.B., Knøchel,
325 S., 2002. Frequency of bacteriocin resistance development and associated fitness costs
326 in *Listeria monocytogenes*. *Applied and Environmental Microbiology* 68, 756-764.
327

328 Hall M.J., Middleton, R.F., Westmacott, D., 1983. The fractional inhibitory
329 concentration (FIC) index as a measure of synergy. *Journal of Antimicrobial*
330 *Chemotherapy* 11, 427-433.
331

332 Le Loir, Y., Baron, F., Gautier, M., 2003. *Staphylococcus aureus* and food poisoning.
333 *Genetics and Molecular Research* 2, 63-76.
334

335 Llull, D., López, R., García, E., 2006. Skl, a novel choline-binding N-acetylmuramoyl-
336 L-alanine amidase of *Streptococcus mitis* SK137 containing a CHAP domain. *FEBS*
337 *Letters* 580, 1959-1964.
338

339 Loeffler, J.M., Fischetti, V.A., 2003. Synergistic lethal effect of a combination of phage
340 lytic enzymes with different activities on penicillin-sensitive and -resistant
341 *Streptococcus pneumoniae* strains. *Antimicrobial Agents and Chemotherapy* 47, 375-
342 377.
343

344 López-Expósito, I., Pellegrini, A., Amigo, L, Recio, I., 2008. Synergistic effect between
345 different milk-derived peptides and proteins. *Journal of Dairy Science* 91, 2184-2189.

346

347 Martínez, B., Obeso, J.M., Rodríguez, A., García, P., 2008. Nisin-bacteriophage
348 crossresistance in *Staphylococcus aureus*. International Journal of Food Microbiology
349 122, 253-258.

350

351 Mazzotta, A.S., Crandall, A.D., Montville, T.J., 1997. Nisin resistance in *Clostridium*
352 *botulinum* spores and vegetative cells. Applied and Environmental Microbiology 6,
353 2654-2659.

354

355 Nascimento, J.G., Guerreiro-Pereira, M.D., Costa, S.F., São-José, C., Santos, M.A.,
356 2008. Nisin-triggered activity of Lys44, the secreted endolysin from *Oenococcus oeni*
357 phage fOg44. Journal of Bacteriology 190, 457-461.

358

359 Obeso, J.M., Martínez, B., Rodríguez, A., García, P., 2008. Lytic activity of the
360 recombinant staphylococcal bacteriophage phiH5 endolysin active against
361 *Staphylococcus aureus* in milk. International Journal of Food Microbiology 128, 212-
362 218.

363

364 Peschel, A., Otto, M., Jack, R.W., Kalbacher, H., Jung, G., Götz F., 1999. Inactivation
365 of the *dlt* operon in *Staphylococcus aureus* confers sensitivity to defensins, protegrins
366 and other antimicrobial peptides. Journal of Biological Chemistry 274, 8405-8410.

367

368 Sambrook, J., Fritsch, E.F., Maniatis, T., 1989. Molecular Cloning: A laboratory
369 manual. 2nd edition. Cold Spring Harbor Laboratory Press.

370

371 Sobrino-López, A., Martín-Belloso, O., 2008. Use of nisin and other bacteriocins for
372 preservation of dairy products. *International Dairy Journal* 18, 329-343.

373

374 White, R.L., Burgess, D. S., Manduru, M., Bosso, J.A., 1996. Comparison of three
375 different *in vitro* methods of detecting synergy: time-kill, checkerboard, and E test.
376 *Antimicrobial Agents and Chemotherapy* 40, 1914-1918.

377

378 **6. Figures**

379

380

381 **Figure 1.** Optimization of turbidity reduction assay conditions for His-tagged LysH5 in
382 the presence of several cations (A) and NaCl (B). (A) Cations were added to the
383 reaction at 0.25 mM (light grey bars), 0.5 mM (dark grey bars), 0.75 mM (black bars),
384 and 1 mM (striped bars). The lytic activity in phosphate buffer 50 mM, pH 7.0 without
385 cations and NaCl was taken as 100% (white bars). Error bars represent standard
386 deviation of three independent measurements.

387

388 **Figure 2.** Minimum Inhibitory Concentration (MIC) and Minimum Lysis Concentration
389 (MLC) of the endolysin LysH5 in the presence of subinhibitory concentrations of nisin.
390 A) *S. aureus* Sa9 culture. The MIC of nisin for *S. aureus* Sa9 was 3 µg/ml in these assay
391 conditions. B) Turbidity reduction assay. The MLC of nisin for *S. aureus* Sa9 was > 6
392 µg/ml in these assay conditions.

393

394 **Figure 3.** Killing of *S. aureus* Sa9 with purified LysH5 and nisin in pasteurized whole
395 milk. A) ♦, cell numbers of *S. aureus* Sa9; ■, LysH5 (7.5 U/ml); □, nisin (0.37 µg/ml);
396 ▲, LysH5 (7.5 U/ml) and nisin (0.37 µg/ml). B) ♦, cell numbers of *S. aureus* Sa9; ■,
397 LysH5 (15 U/ml); □, nisin (0.75 µg/ml); ▲, LysH5 (15 U/ml) and nisin (0.75 µg/ml).
398 Values are the means of two independent experiments with standard deviation indicated
399 by vertical bars.

400

401

402

403

A

404

405


406

407

408

409

410



411

412

413

414

415

416

417

418

419

420

421

422

423


424

425

426

427

B



428

429

A

430


431

432

433

434

435



436

437

438

439

440

441

442

443

444

445

446

447

448


449

450

451

452

B



453

454

